US2013331352A1PendingUtilityA1

Combination of Components for the Prevention and Treatment of Frailty

60
Assignee: HAGEMAN ROBERT JOHAN JOSEPHPriority: Dec 28, 2010Filed: Dec 28, 2011Published: Dec 12, 2013
Est. expiryDec 28, 2030(~4.5 yrs left)· nominal 20-yr term from priority
Inventors:Robert Johan Joseph HagemanMattheus Cornelis De WildeMartine GroenendijkPatrick Joseph Gerardus Hendrikus Kamphuis
A61K 33/04A61K 31/375C07H 19/06A61K 31/675A23L 33/12A23L 33/13A61K 31/202A61K 31/7072A61K 45/06A23V 2002/00A61K 31/714A61K 31/683A23L 33/40A61K 31/661A61K 31/14C07H 19/052A61K 31/519A61K 31/355A61K 31/685A23L 33/15A61K 31/20A61K 31/4415A61K 31/70A61K 31/7068A61K 31/7056A61P 25/28A61K 31/715A61K 31/688A61K 31/4985A61K 31/44A23L 33/14
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Composition comprising at least two components, more preferably at least three components, more preferably at least four components, selected from the group of (i) a nucleoside equivalent, (ii) an ω-3 polyunsaturated fatty acid selected from the group of DHA, DPA and EPA, (iii) a vitamin B, (iv) a phospholipid, (v) an antioxidant and (vi) a choline, with the proviso that at least component (i) or (iii) is present, for use in the prevention or treatment of frailty in a mammal, wherein frailty is determined by compliance with at least 2 criterions, preferably 3 criterions, selected from the group of muscle weakness, excessive feelings of exhaustion or fatigue, abnormally low physical activity, slow or unsteady gait, weight loss, and neurological dysfunction.

Claims

exact text as granted — not AI-modified
1 . Nutritional or pharmaceutical composition comprising at least two components selected from the group consisting of (i) a nucleoside equivalent, (ii) an ω-3 polyunsaturated fatty acid selected from the group consisting of DHA, DPA and EPA, (iii) a vitamin B selected from the group consisting of vitamin B6, vitamin B12 and vitamin B9, (iv) a phospholipid, (v) an antioxidant selected from the group consisting of vitamin C, vitamin E and selenium and (vi) a choline, with the proviso that at least component (i) or (iii) is present. 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . Composition according to  claim 1 , wherein the composition comprises UMP. 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . Composition according to  claim 1 , wherein the composition comprises at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine. 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . Composition according to  claim 1 , wherein the composition comprises (i) UMP, (ii) DHA and EPA, (iii) vitamin B6, vitamin B12 and vitamin B9, (iv) at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine, (v) vitamin C, vitamin E and selenium and (vi) choline chloride. 
     
     
         18 . Composition comprising at least (i) a uridine equivalent, (ii) an ω-3 polyunsaturated fatty acid selected from the group consisting of DHA, DPA and EPA, (iii) a vitamin B, (iv) a phospholipid, (v) an antioxidant selected from the group consisting of vitamin C, vitamin E and selenium, and (vi) a choline. 
     
     
         19 . Composition according to  claim 1  being a nutritional composition comprising at least a whey protein. 
     
     
         20 . Composition according to  claim 19 , wherein the composition has a nutritional value of at least 50 kcal per 100 ml. 
     
     
         21 . A method of preventing or treating frailty in a mammal comprising administering a composition comprising at least two components selected from the group consisting of (i) a nucleoside equivalent, (ii) an ω-3 polyunsaturated fatty acid selected from the group consisting of DHA, DPA and EPA, (iii) a vitamin B, (iv) a phospholipid, (v) an antioxidant and (vi) a choline, with the proviso that at least component (i) or (iii) is present. 
     
     
         22 . The method of  claim 21  comprising administering the composition comprising at least three components selected from the group consisting of (i) a nucleoside equivalent, (ii) an ω-3 polyunsaturated fatty acid selected from the group consisting of DHA, DPA and EPA, (iii) a vitamin B, (iv) a phospholipid, (v) an antioxidant and (vi) a choline, with the proviso that at least component (i) or (iii) is present. 
     
     
         23 . The method of  claim 21  comprising administering the composition comprising at least four components selected from the group consisting of (i) a nucleoside equivalent, (ii) an ω-3 polyunsaturated fatty acid selected from the group consisting of DHA, DPA and EPA, (iii) a vitamin B, (iv) a phospholipid, (v) an antioxidant and (vi) a choline, with the proviso that at least component (i) or (iii) is present. 
     
     
         24 . The method of  claim 21  wherein frailty is determined by compliance with at least 2 criterions selected from the group consisting of muscle weakness, excessive feelings of exhaustion or fatigue, abnormally low physical activity, slow or unsteady gait, weight loss, and neurological dysfunction. 
     
     
         25 . The method of  claim 21  comprising administering the composition to increase one or more of body weight, body mass index, lean body weight, muscle mass, muscle strength or muscle function. 
     
     
         26 . The method of  claim 21  wherein the mammal is an elderly human. 
     
     
         27 . The method of  claim 21  wherein the mammal is a human prone to or suffering from cognitive decline or dementia. 
     
     
         28 . The method of  claim 21  wherein the mammal is a human prone to or suffering from senile dementia. 
     
     
         29 . The method of  claim 21  wherein the mammal is a human prone to or suffering from Alzheimer's disease. 
     
     
         30 . The method of  claim 21  wherein the mammal is suffering from a prodromal form of dementia. 
     
     
         31 . The method of  claim 21  wherein the mammal has a BMI below 26 kg/m 2 . 
     
     
         32 . The method of  claim 21  wherein the mammal has a BMI below 23.5 kg/m 2 . 
     
     
         33 . The method of  claim 23  wherein the composition comprises UMP, DHA, EPA, at least one vitamin selected from the group consisting of vitamin B6, vitamin B12 and vitamin B9, and at least one antioxidant selected from the group consisting of vitamin C, vitamin E and selenium. 
     
     
         34 . The method of  claim 21  wherein the composition comprises at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine. 
     
     
         35 . The method of  claim 21  wherein the composition is a nutritional composition comprising at least a whey protein. 
     
     
         36 . The method of  claim 21  wherein the composition has a nutritional value of at least 50 kcal per 100 ml of composition. 
     
     
         37 . The method of  claim 21  wherein the composition has a nutritional value of at least 100 to 300 kcal per 100 ml of composition.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.